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INTRODUCTION
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [1 && ]. In this context, the organ dysfunction is identified clinically by an increase in the Sequential (Sepsis-related) Organ Failure Assessment score of 2 points or more [1 && ,2]. Septic shock is defined as a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone [1 && ]. The clinical criteria for identifying septic shock patients is a vasopressor requirement to maintain a mean arterial pressure (MAP) of 65 mmHg or greater and serum lactate level greater than 2 mmol/l (>18 mg/dl) in the absence of hypovolemia [3] . Resuscitation is the key intervention for treating macro and microcirculatory abnormalities commonly observed in sepsis and septic shock patients [4] and resuscitation also forms part of the 3-h and 6-h bundles proposed in the Surviving Sepsis Campaign guidelines [5] . In this review, we discuss sepsis-related microcirculation and macrocirculation abnormalities, resuscitation goals in guidelines, microcirculation as a focus of early
MICROCIRCULATION AND MACROCIRCULATION ABNORMALITIES ARE COMMON IN SEPSIS AND SEPTIC SHOCK
Microcirculation refers to circulation within the blood vessels less than 100-150 mm in diameter (such as arterioles, capillaries, venules, and lymphatics) and the associated cells such as endothelium, smooth muscle, erythrocytes, leukocytes, and platelets. The tools required to measure microcirculatory flow directly are not routinely available. Notwithstanding, tissue perfusion-based markers [6] such as lactate, mixed/central venous oxygen saturation (ScvO 2 ), and central venous-arterial partial pressure of carbon dioxide difference (dPCO 2 ) [7, 8] , constitute indirect markers of adequate global microcirculation. Microcirculation could also be assessed to understand the homogeneity in blood flow by assessing number of patent capillaries, referred to as functional capillary density.
In sepsis, the microcirculation is profoundly altered because of local and systemic host responses. In health, the endothelium acts as continuous and anticoagulant barrier between circulating blood and tissue. In sepsis, the endothelial barrier is disrupted resulting in enhanced coagulation, extravasation of fluids, and ahdesion of activated leukocytes creating a vicious cycle. This perpetuates inflammation, coagulopathy, and endothelial injury [9 && ]. The associated impaired vascular smooth muscle tone, relative hypovolemia, and a reduction in the functional capillary density results in a heterogeneous combination of microcirculatory units that have lost their ability to regulate vascular tone. Constricted arterioles coexist with vasodilated units. These changes result in inefficient microcirculation creating an oxygen partial pressure gap evidenced by the reduced capillary oxygen partial pressure, increased venous oxygen partial pressure, and impaired mitochondrial oxygen extraction [10 && ,11] . The circulation in larger blood vessels is referred to as macrocirculation. Indicators of macrocirculation include central venous pressure (CVP), pulmonary wedge pressure, arterial blood pressure (BP), cardiac output (CO), arterial oxygen content and delivery. Similar to microcirculatory changes, the macrocirculation abnormalities in sepsis are also heterogeneous. In addition, there is an acute reversible myocardial depression affecting both ventricles, with altered myocytes and gene expression abnormalities suggestive of impaired sarcomere contraction and impaired excitation-contraction coupling [12, 13] .
EARLY RESUSCITATION IN SEPSIS AND SEPTIC SHOCK
In 2001, Rivers et al. [14] reported a 263 patient single-centre randomized controlled trial (RCT) of early goal-directed therapy (EGDT) versus standard care for patients with severe sepsis or septic shock that showed 16% absolute reduction in in-hospital mortality with EGDT. This EGDT consisted of first achieving the macrocirculation goals (CVP ! 8-12 mmHg, MAP ! 65 mmHg), followed by the microcirculation target of ScvO 2 ! 70%. The interventions to achieve these macrocirculation goals were fluids and vasopressors and those for microcirculation goals were red blood transfusion to haemoglobin more than 10 g/l and/or inotropic agents to improve CO. The key differences between the EGDT arm and usual care arm in term of interventions administered between 0 and 6 h were -significantly greater volume of fluids, red blood cells, and inotropic agents. This trial formed the basis for the resuscitation goals in the previous Surviving Sepsis Campaign guidelines [15] . Goals during the first 6 h of resuscitation: CVP ¼ 8-12; MAP at least 65 mmHg; urine output at least 0.5 ml/kg/h and ScvO 2 superior vena cava or mixed venous oxygen saturation ! 70 or 65%, respectively.
Between 2008 and 2014, three further multicentre RCTs compared EGDT with usual care, using a similar protocol to Rivers et al. [14] enrolling a total of 4211 patients, from the United States (Protocolized Care for Early Septic Shock), Australasia (Australasian Resuscitation in Sepsis Evaluation), and the United Kingdom (Protocolized Management in Sepsis) [16] . In addition to trial-level meta-analyses [16] , the authors also harmonized
KEY POINTS
The Surviving Sepsis Campaign guidelines provide a framework for managing sepsis patients.
Early antibiotic therapy and fluid resuscitation are major interventions in sepsis patients.
Emerging evidence suggests discordance between macrocirculatory and microcirculatory optimization following resuscitation.
As resuscitation-associated-positive fluid balance and high-dose vasopressors are associated with adverse outcomes in sepsis and septic shock, trials of fluid restriction, and lower BP targets are ongoing.
data from these three trials and reported an individual patient-level meta-analysis [17 && ], to explore the overall average treatment effect and key predefined subgroups effects of EGDT compared with usual care. The 90-day mortality did not differ between the EGDT therapy (24.9%) and usual care (25.4%) groups with a nonsignificant adjusted odds ratio [95% confidence interval (CI)] of 0.97 (0.82-1.14). The EGDT treatment effect did not vary by severity of illness. Based on these results, the current Surviving Sepsis Campaign guidelines [5] strongly recommend administering at least 30 ml/kg of intravenous crystalloid fluids within the first 3 h, whilst acknowledging that this is based on low-quality of evidence. These guidelines also recommend a target MAP ! 65 mmHg and suggest guiding resuscitation to normalize lactate in patients with elevated lactate levels, which is a weak recommendation based on low-quality evidence, but addresses a microcirculation goal.
IS THERE A ROLE FOR TARGETING MICROCIRCULATION DURING EARLY RESUSCITATION?
The microcirculation goals addressed in RCTs include a reduction in serum lactate concentrations compared with either ScvO 2 in the emergency department (The LactATES trial [18] ) or to usual care in the ICU [19] . The LactATES trial was a noninferiority RCT in 300 patients and compared the control group who received targeted resuscitation to meet thresholds of CVP, followed by MAP, and then ScvO2 of 70% or more to the lactate clearance group that had similar targeted thresholds in CVP, MAP, and then lactate clearance of 10% or more. This trial highlighted that lactate clearance is noninferior to ScvO 2 -based resuscitation. Of note, a prespecified subgroup analysis from this trial highlighted that achievement of only the ScvO 2 goal was associated with a higher mortality compared with achievement of only the lactate clearance goal only (41 versus 8% and difference in proportion ¼ 33%; 95% CI 9-55%). Although these underpowered subgroup analyses needs testing in RCTs prior to clinical adoption [20] , it does highlight the value of studying lactate kinetics. In the ICU, Jansen et al. [19] evaluated a complex protocol to target a lactate clearance of 20% or more. Although, there was no difference in unadjusted mortality between the usual care arm and lactate clearance arm, the covariate adjusted OR was significantly lower in the lactate clearance arm. Patients in the lactate clearance arm received more fluids and, as stipulated by the experimental protocol, 42.5% received vasodilators during the first 8 h of resuscitation with the objective of 'opening' microcirculatory units. This approach challenges the more traditional goals of resuscitation (e.g. MAP of 65 mmHg). Vasopressors, which are commonly used to achieve MAP targets, could be reduced to the extent that minimal perfusion can be maintained at lower MAP values and, ultimately, administering vasodilators therapy could improve microcirculatory flow. However, although lactate clearance is undisputedly a favourable prognostic sign [21] , high lactate levels are not specific for tissue dysoxia in sepsis and catecholamines' directly increase lactate levels via increased glycolysis [22] . Furthermore, the Surviving Sepsis Campaign guideline panel made a weak recommendation for lactateguided resuscitation protocols, based on low-quality evidence, and did not address vasodilators, citing methodological limitations in the supporting literature.
Arteriovenous CO 2 gradients constitute another potential resuscitation target [23] . In theory, the difference between venous and arterial carbon dioxide blood content increases in proportion with the mismatch between CO and the CO 2 production of carbon dioxide. Elevated dPCO 2 gradients (the normal range is 2-6 mmHg) may indicate inadequate blood flow relative to metabolism before lactate levels rise. However, CO 2 metabolism is complex and the value of dPCO 2 gradients as resuscitation targets hinges on numerous assumptions. Moreover, the overall effects of resuscitation protocols guided by dPCO 2 gradients remain unknown. Finally, in a provocative study, Marik et al. [24] highlight the potential clinical benefits of combined early administration of intravenous vitamin C, together with corticosteroids and thiamine with biological plausibility arguments that point toward the microvasculature effects of this intervention. In summary, well designed and adequately powered experiments on the role of microvascular resuscitation in sepsis and septic shock patients are urgently needed.
FLUIDS
The theoretical goals of fluid administration during initial resuscitation of sepsis/septic shock include restoration of stressed intravascular volume and optimization of ventricular preload. The amount and type of fluid therapy remain contentious. Although fluid boluses may augment immediate haemodynamic parameters, concerns exist in regard to the transient nature of effect, the impact on the microcirculation and risk of iatrogenic complications [25] [26] [27] . There remains a similar lack of clarity around the most appropriate type of fluid to administer in the early phases of resuscitation in septic shock. Hydroxyethyl starch solutions are no longer widely recommended based on a lack of overall benefit and potential harm [28] . Similarly, the potential efficacy signal in the sepsis subgroup for Albumin-based resuscitation could not be confirmed in a recent RCT [29] . In the absence of any clearly demonstrated benefit for colloids, initial crystalloid resuscitation is still recommended in the 2016 Surviving Sepsis guidelines, although concerns persist about the multiple potential sideeffects of resuscitation with normal saline including renal, proinflammatory, anticoagulant, and acidbase associations. Balanced solutions have theoretical advantages, although a clear benefit is yet to be consistently demonstrated [12] . Whichever fluid and volume is chosen, with limited and conflicting evidence in the setting of septic shock, it is important that the therapeutic agent is considered a drug, and administered with such caution.
Large volumes of resuscitation fluids administered to septic shock patients result in a positive cumulative fluid balance. This increasing cumulative balance impairs microcirculation and is an independent risk factor for mortality in sepsis and septic shock patients [30, 31] . Furthermore, in children with severe infection, when either saline or albumin fluid boluses were administered over and above the maintenance fluids, the 48-h mortality was significantly higher [32] . These observations resulted in a feasibility RCT of conservative versus liberal approach to fluid therapy in septic shock (CLASSIC trial). This trial highlighted feasibility for this approach with significantly lower cumulative resuscitation fluid in the ICU at day 5 after randomization and during the entire ICU stay in the restricted group versus the standard care group [mean differences À1.2 l (95% CI À2.0 to À0.4); and À1.4 l (95% CI À2.4 to À0.4); P < 0.001) without increasing the risk of adverse outcomes [33] . A initial approach involving passive leg raising to assess fluid responsiveness may reduce the total volume of fluid administered in sepsis and septic shock patients [34] .
VASOPRESSORS AND INOTROPIC AGENTS
Vasopressors, like fluids, are an intuitive component of resuscitation bundles. In theory, vasopressors correct excessive vasodilatation at the root of the alleged pathological causal pathway. However, hypotension does not necessarily signify impaired organ perfusion and normal BP does not guarantee adequate tissue perfusion. By Poiseuille's law, the blood vessel's radius has a much more profound impact on flow than the pressure gradient. Because vasopressors induce vasoconstriction (i.e. reducing the radius of vessels), they may reduce organ perfusion despite achieving BP targets. In addition, vasopressors themselves may impair microcirculatory flow [35] . For example, clinicians may be inclined to attribute worsening signs of shock to the underlying illness and intensify therapy, unsuspecting of the fact that it is their intervention that is the culprit. Accordingly, when administering vasoactive agents, clinicians should consider iatrogenic complications in the differential diagnosis of any clinical deterioration. Recent studies raise concern regarding the overall safety of liberal vasopressor use in sepsis. Until adequately powered clinical trials ascertain the overall effects of more restrictive MAP targets, the overall benefit of currently recommended MAP targets hinges on scant evidence [36] .
When discussing vasopressor therapy, the role of relative vasopressin deficiency and utility of vasopressin as a vasopressor in septic shock have to be considered [37] . In a trial of vasopressin versus norepinephrine and steroids versus placebo, using a factorial trial design, with renal failure free days as primary outcome, vasopressin compared with norepinephrine did not improve the number of kidney failure-free days [38] . The hypothesis from subgroup analyses from earlier vasopressin trials [39] is that patients with lower severity of illness may benefit the most. This hypothesis should be tested in the context of increasing vasopressin use in patients with septic shock [40] . The circulatory changes in sepsis could also be secondary to abnormalities in the renin-angiotensin system and exogenously administered exogenous angiotensin II could be an useful vasopressor in septic shock patients [41] . Recently, in patients with catecholamine resistant vasodilatory shock, angiotensin II administration was associated with improved BP, which was the primary outcome. In this trial, nearly 75% of patients the aetiology of catecholamine resistant vasodilatory state was septic shock, implying potential utility for angiotensin II in septic shock management, once mortality benefit is confirmed [42] .
Levosimendan is a calcium-sensitizing drug that has multiple effects aside from positive inotropy, which are potentially beneficial in sepsis. For example, in a recent pilot RCT in 20 patients, levosimendan lowered the lactate/pyruvate ratio, which suggests beneficial effect on cellular metabolic alterations in septic shock [43] . However, a large superiority trial that tested the hypothesis that levosimendan would reduce the severity of organ dysfunction in adults with sepsis, in 516 adult patients with sepsis. In this trial, levosimendan compared to placebo was not associated with less severe organ dysfunction or lower mortality. Importantly, there was a higher risk of supraventricular arrhythmias and weaning failure in the levosimendan-treated patients in this trial [44] . Given the lack of efficacy of levosimenden in cardiac surgical patients with impaired left ventricular function [45, 46] , further studies to enrich sepsis population that is likely to benefit from levosimenden is required prior to widespread clinical use.
CONCLUSION
Septic shock is common and carries a high risk of death. Early administration of antibiotics and targeted resuscitation remain the cornerstones of care. There is increasing evidence that some conventional approaches with large volume resuscitation and high-dose vasopressors may not be beneficial, or even potentially harmful. Distinction should be drawn between microcirculatory and macrocirculatory changes and resuscitation. Individualized resuscitation focused on microcirculation and lower BP targets may have theoretical advantages over macrocirculatory goals of care applied invariably to all patients. However, conclusive evidence will require adequately powered experiments.
